PharmaCyte Biotech, Inc. (PMCB)

US — Healthcare Sector
Peers: TCRT  AIM  ADXN  QLGN  PLRZ  ALZN  BCLI  VYNE  NRSN  IBO 

Automate Your Wheel Strategy on PMCB

With Tiblio's Option Bot, you can configure your own wheel strategy including PMCB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PMCB
  • Rev/Share 0.0
  • Book/Share 6.4145
  • PB 0.1496
  • Debt/Equity 0.0
  • CurrentRatio 18.0102
  • ROIC -0.0898

 

  • MktCap 6522589.0
  • FreeCF/Share -0.6767
  • PFCF -1.4183
  • PE -5.7952
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -0.0251

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 5
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
PMCB, TNFA
Published: September 02, 2025 by: Business Wire
Sentiment: Neutral

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced that it has increased its stake in TNF Pharmaceuticals (Nasdaq: TNFA, “TNF”) by an additional $3 million. The Company does so to help support TNF's recent acquisition of a license with LightSolver, Ltd. (“LightSolver”), a company recognized by Gartner and the World Economic Forum for its breakthrough innovations. The license is for its revolutionary processing accelerator designed.

Read More
image for news PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
PMCB
Published: August 20, 2025 by: Business Wire
Sentiment: Neutral

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the closing of its previously announced $7 million financing. As of April 30, 2025, PharmaCyte had approximately $15.5 million in cash and also holds over $30 million of securities as reflected in the Company's most recent 10K. With the addition of the $7 million in proceeds from this financing, the Company's balance sheet has been further strengthened, providing significant finan.

Read More
image for news PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing

About PharmaCyte Biotech, Inc. (PMCB)

  • IPO Date 2013-01-02
  • Website https://pharmacyte.com
  • Industry Biotechnology
  • CEO Joshua N. Silverman
  • Employees 2
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.